The Carlyle Group has formally engaged Goldman Sachs and JM Financial to advise on a potential $400 million IPO of its India-based healthcare RCM platform. The timeline is notable: Carlyle acquired Knack RCM and EqualizeRCM in April, merged them, and is already lining up bankers. This is PE moving at a pace the RCM market hasn't seen.
Carlyle has engaged two advisers — Goldman Sachs and India-based JM Financial — to manage the IPO process for its consolidated RCM platform, now operating under the Knack RCM brand. The offering is targeting up to $400 million in proceeds, with a launch window of late 2026 or early 2027.
The platform was assembled fast. Carlyle acquired both Knack RCM (a Woodbridge, New Jersey-based RCM services firm) and EqualizeRCM in April 2026. By June, they were taking banker pitches. By July 3, Goldman and JM Financial were formally hired. That's a roughly 90-day sprint from acquisition close to IPO banker engagement.
employees across 10 delivery centers in India, the Philippines, and the US — the scale Carlyle is now moving to public markets.
The platform supports US healthcare clients across clinical, financial, and technology functions — the full revenue cycle stack. India is the operating core; the US is the client base. That model is now heading to the India Stock Exchange at a $400M raise target.
India's IPO market is a rare bright spot. The Nifty 50 is down more than 10% this year, but healthcare listings continue to find strong demand — hospital operators like Manipal Health Enterprises and General Atlantic-backed ASG Hospital are planning their own IPOs. Carlyle is surfing the same wave.
The choice of India as the listing venue rather than the US or UK is deliberate. Knack RCM's delivery infrastructure is primarily Indian. The investor base that understands the offshore healthcare services model — and is willing to pay multiples for it — is concentrated in Indian institutional capital markets. JM Financial's inclusion as co-adviser confirms this is a domestic Indian market play, not a cross-listed structure.
Carlyle has not disclosed a target valuation or P/E multiple. The $400M figure is raise size, not implied valuation. For an 8,000-person offshore RCM platform, market comps would put the implied valuation well north of $1B — but nothing is confirmed. A representative for Carlyle declined to comment.
This move has downstream implications for US healthcare finance teams that have nothing to do with India's capital markets.
When a company with 8,000+ offshore FTEs — doing clinical, financial, and technology revenue cycle work for US hospital systems — goes public at a $400M raise, it validates the offshore-first RCM model at the highest institutional level. Public market scrutiny forces transparency on unit economics. That transparency will inevitably flow back into US vendor contract negotiations.
The speed matters. April acquisition. June banker pitches. July formal engagement. That's not how traditional PE operates — typical hold periods run 5–7 years before exit. Carlyle is running a different playbook: acquire, merge, and move to liquidity event inside one calendar year.
Two possibilities explain it:
Either way, the signal is the same: offshore RCM at scale is ready for public markets. That's a different category of institutional validation than any series of press releases or analyst reports.
We covered the original Carlyle acquisition and merger in April — Carlyle Acquires Knack RCM + EqualizeRCM to Build AI-Native Global RCM Platform →
Deal signals, payor shifts, and vendor moves — delivered every Tuesday to revenue cycle professionals.
RevCycleAI · Published July 4, 2026 · Source: Bloomberg